Poorest children missing more school and further behind after Covid
The poorest children are missing more school and falling further behind classmates, research shared with the BBC suggests.
According to new analysis by the Education Policy Institute (EPI) - which looked at pupil performance after the Covid-19 pandemic - children from the lowest income families are now up to 19 months behind peers by the time they are 16 years old.
Education Secretary Bridget Phillipson told BBC Panorama Covid had led to a "serious and profound shift" in attitudes to attendance. She said lockdowns had cast "a long shadow" over the life chances of the youngest children.
The latest statistics for persistent absence show 15% of primary children in England have missed at least one in ten days of school this school year - up from about 8% before Covid.
It comes as the gap between the poorest students and other pupils had mainly narrowed before the pandemic, following years of effort by schools.
However, the report suggests it is getting worse. The gap - which is measured using GCSE results - would reduce from 19 months to 15 months of learning if school attendance was the same for all pupils, it says.
Natalie Perera, from the EPI, said it is the first time "a very clear link" has been made between how much children from the lowest income families attend school, and how far behind other pupils they have fallen.
Her team looked specifically at children who have received free school meals in the past six years, which means the family income is less than £7,400 a year after tax and not including benefits.
Ms Perera said more research was needed to understand why these children struggled to be in school, with possible factors including poor housing and mental health.
It is five years since the UK went into lockdown, when schools closed to most children.
Playgroups and nurseries also shut, with parents of babies and toddlers isolated from their extended family. There were other changes too, as health visitors were re-deployed or in contact with parents only online.
Panorama has heard from families and teachers about the impact on these children, who are just starting or are still in primary school.
Schools say some have delayed speech and understanding of words, or have slower social or emotional development, or they lack basic skills normally picked up through play.
Professor Catherine Davies, from the University of Leeds, says some children missed out on "fundamental skills" they need to make sense of school and get on with wider groups.
Covid inquiry investigates impact on children
At Queen's Drive Primary School, in Preston, teaching assistant Sarah Barraclough has been trained in a national programme to help four and five-year-olds in England with speech and language.
She says the impact of Covid has been "huge" and if they don't learn to say and understand more words, children then become isolated. "You're lonely and not getting involved in the games in the playground," she says.
Emaan, now aged four, was born during the first UK lockdown and is one of the children receiving help through Nuffield Early Language Intervention (NELI).
His parents, Ruby and Charles, really notice the difference between Emaan and his older brother. During the pandemic, Emaan barely went out and met other people.
Charles says there is a "stark difference" between their sons and that Emaan is a lot more clingy.
The NELI programme to train teaching assistants is funded until the end of this school year in England. But beyond then, funding has not yet been confirmed.
The Covid kids starting school unable to speak
The government has set a 2028 target for 75% of children - up from 68% - to reach a good level of development by the time they leave reception.
Some of the cultural shifts caused by the lockdowns and partial school closures could prove to be the hardest to resolve.
The education secretary told the BBC the pandemic had profoundly changed attitudes towards attendance. She said it was important the youngest pupils got the "support they need to thrive".

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Biden's COVID czar hammers RFK Jr. over vaccine panel overhaul
Former White House COVID-19 response coordinator Ashish Jha, who served under former President Biden, criticized the decision by Health and Human Services Secretary Robert F. Kennedy Jr. to fire all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel. Kennedy announced the decision in an op-ed for The Wall Street Journal on Monday, saying, 'A clean sweep is needed to re-establish public confidence in vaccine science.' But in an interview with CNN's Wolf Blitzer, Jha pushed back against Kennedy's reasoning. 'Look, what he said in his op-ed was a series of nonsense about a group of individuals, experts …who shape what vaccines, if any, are going to be available to the American people,' Jha said in the interview. 'So obviously this is very concerning,' he continued. 'We'll have to see who he appoints next. But this is a step in the wrong direction.' Jha said he is concerned about what the move foretells about the secretary's agenda on vaccines. Jha pointed to what he characterized as a lackluster response from the secretary to 'the worst measles outbreak of the last 25 years.' He also expressed concern regarding Kennedy's raising questions about vaccines causing autism, which Jha dismissed and said was 'settled science.' 'Then you put this in the middle of all of that,' Jha said, referring to the vaccine panel sweep, 'and what you have is a pretty clear picture that what Secretary Kennedy is trying to do is make sure that vaccines are not readily available to Americans, not just for kids, for the elderly.' 'He could go pretty far with this move, and I really am worried about where we're headed,' Jha continued. He said he's particularly concerned about the effect Kennedy's move will have on kids and whether they will continue having access to certain vaccines in the future. 'Kids rely on vaccines. I'm worried about whether the next generation of kids are going to have access to polio vaccines and measles vaccines. That's where we're heading. That's what we have to push back against.' Kennedy said in his op-ed that he was removing every member of the panel to give the Trump administration an opportunity to appoint its own members. Kennedy has long accused members of the Advisory Committee on Immunization Practices of having conflicts of interest, sparking concern among vaccine advocates that he would seek to install members who are far more skeptical of approving new vaccines. But Jha pushed back against criticism that the panel was all Biden-appointed experts, saying, 'When the Biden administration came in, almost all of the appointees had come from the first Trump administration.' 'That was fine because they were good people,' he said. 'They were experts. Right now, it's the same thing. The people he is firing are experts — like a nurse in Illinois who spent her entire career getting kids vaccinated, cancer doctors from Memorial Sloan Kettering — like these are really good people.' 'And generally, CDC has not worried about when were they appointed. The question is, are they good and are they conflict free.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
UAMS chancellor stepping down after 7 years, returning to faculty
UAMS Chancellor Cam Patterson announces a new $31.7 million grant from the National Institutes of Health on July 10, 2024. (Mary Hennigan/Arkansas Advocate) The leader of Arkansas' largest healthcare system will step down after seven years for personal and medical reasons, the University of Arkansas for Medical Sciences announced Tuesday in a news release. Dr. Cam Patterson became the university's chancellor in June 2018. By giving up his position as chancellor and as UAMS Health CEO, he will return to being a faculty member in the university's cardiology department. Patterson 'is facing medical and personal issues that require more attention than he can give them while serving in the chancellor's position,' according to UAMS' news release. 'The work our team has done at UAMS over the last seven-plus years has been the high point of my career,' Patterson said in the release. 'We have a lot to be proud of and I've been the luckiest guy to be a part of it. I am excited about the opportunity to return to the faculty and engage more deeply in the academic and clinical missions at our institution.' UAMS System President Jay Silveria praised Patterson's leadership tenure in the release. 'Leading UAMS is a demanding task, and I appreciate Dr. Patterson's need to do what he feels is best for himself and his family and for the long-term success of the university,' Silveria said. 'His contributions to UAMS came through unusually restrictive times, and he should be celebrated for his efforts to push the institution forward while navigating a challenging environment.' Patterson 'oversaw both challenges and improvement in the university's economic outlook, despite the myriad issues presented by the COVID-19 pandemic and other unforeseen variables,' the release states. One such challenge was a conflict between state and federal mandates regarding COVID-19 vaccinations. The federal Centers for Medicare and Medicaid Services issued a mandate in November 2021 for health workers to be fully vaccinated or receive exemptions, with noncompliant facilities at risk of losing federal funding. The rule directly conflicted with a 2021 Arkansas law that said COVID-19 vaccination 'shall not be a condition of education, employment, entry, or services from the state or a state agency or entity' unless lawmakers approved an exception. Patterson sought an exemption and defended this decision before a legislative committee. Silveria will name an interim UAMS chancellor 'in the coming weeks' and start a national search for Patterson's permanent successor, the news release states. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
2 hours ago
- Yahoo
India brought forward its TB elimination deadline - but can it be met?
Atul Kumar (name changed) anxiously paced the corridor of a public hospital in India's capital Delhi. A small-appliance mechanic, he was struggling to secure medicines for his 26-year-old daughter who suffers from drug-resistant tuberculosis (TB). Mr Kumar said his daughter needed 22 tablets of Monopas, an antibiotic used for treating TB, every day. "In the past 18 months, I haven't received government-supplied medicine for even two full months," he told BBC Hindi in January, months before India's declared deadline to eliminate the infectious disease. Forced to buy costly drugs from private pharmacies, Mr Kumar was drowning in debt. A week's supply cost 1,400 rupees ($16; £12), more than half his weekly income. After the BBC raised the issue, authorities supplied the medicines Mr Kumar's daughter needed. Federal Health Secretary Punya Salila Srivastava said that the government usually acts quickly to fix medicine access issues when alerted. Mr Kumar's daughter is one of millions of Indians suffering from tuberculosis, a bacterial disease that infects the lungs and is spread when the infected person coughs or sneezes. India, home to 27% of the world's tuberculosis cases, sees two TB-related deaths every three minutes. India's TB burden has long been tied to poor case detection, underfunding and erratic drug supply. Despite this grim reality, the country has set an ambitious goal. It aims to eliminate TB by the end of 2025, five years ahead of the global target set by the World Health Organization (WHO) and United Nations member states. Elimination, as defined by the WHO, means cutting new TB cases by 80% and deaths by 90% compared with 2015 levels. But visits to TB centres in Delhi and the eastern state of Odisha revealed troubling gaps in the government's TB programme. In Odisha's Khordha district, around 30km (18.6 miles) from state capital Bhubaneshwar, 32-year-old day-labourer Kanhucharan Sahu is struggling to continue his two-year-old daughter's TB treatment, with government medicines unavailable for three months and private ones costing 1,500 rupees a month - an unbearable burden. "We can't see her suffer anymore," he says, his voice breaking. "We even thought of abandoning her." At Odisha's local TB office, officials promised to review Sahu's case, but a staffer admitted, "We rarely get the medicines we need, so we ration them." Mr Sahu says he hasn't received the promised 1,000 rupees monthly support from the federal government and at the local TB office, officials admit to chronic shortages, leaving families like his adrift in a failing system. Vijayalakshmi Routray, who runs the patient support group Sahyog, says medicine shortages are now routine, with government outlets often running dry. "How can we talk about ending TB with such gaps?" she asks. There are other hurdles too - for example, changing treatment centres involves navigating complex bureaucracy, a barrier that often leads to missed doses and incomplete care. This poses a major hurdle for India's vast population of migrant workers. At a hospital near Khordha, 50-year-old Babu Nayak, a sweeper who was diagnosed with TB in 2023, struggles to continue his treatment. He was regularly forced to travel 100km to his village for medicines as officials insisted he collect them from the original centre where he was diagnosed and first treated. "It became too difficult," he says. Unable to travel so often, Mr Nayak stopped taking the medication altogether. "It was a mistake," he admitted, after contracting TB again last year and being hospitalised. At his hospital, no TB specialist was available, highlighting another critical gap in India's fight: a shortage of frontline health workers. The BBC shared its findings with the federal health ministry and officials in charge of the TB programme in Delhi and Odisha. There was no response despite repeated reminders. A 2023 parliamentary report showed there were many vacant roles across all levels of the TB programme, affecting diagnosis, treatment and follow-up - especially in rural and underserved areas. Can vaccines help India triumph over tuberculosis? In 2018, when Prime Minister Narendra Modi brought forward India's TB elimination target to 2025, he cited the government's intensified efforts as a reason for optimism. Two years later, the Covid pandemic disrupted TB elimination efforts globally, delaying diagnosis, diverting resources and pausing routine services. Medicine shortages, staff constraints and weakened patient monitoring have further widened the gap between ambition and reality. Despite these challenges, India has made some progress. Over the past decade, the country has reduced its tuberculosis-related mortality. Between 2015 and 2023, TB deaths declined from 28 to 22 per 100,000 people. This figure, however, is still high when compared with the global average which stands at 15.5. The number of reported cases has gone up, which the government credits to its targeted outreach and screening programmes. In 2024, India recorded 2.6 million TB cases, up from 2.5 million in 2023. Federal Health Minister JP Nadda recently touted innovations like handheld X-ray devices as game-changers in expanding testing. But on the ground, the picture is less optimistic. "I still see some patients come to me with reports of sputum (phlegm) smear microscopy for TB, a test which has a much lower detection rate as compared to genetic tests," says Dr Lancelot Pinto, a Mumbai-based epidemiologist. Genetic tests, which includes RT-PCR machines - widely used to diagnose HIV, influenza and most recently, Covid-19 - and Nucleic Acid Amplification Testing, also examine the sputum sample but with greater sensitivity and in a shorter timeframe. Besides, the tests can reveal whether the TB strain is drug-resistant or sensitive, something that microscopic testing can't do, Dr Pinto says. The gap, he adds, stems not just from lack of awareness but from limited access to modern tests. "Genetic testing is free at government hospitals but not uniformly available, with only a few states being able to provide it." In May, Modi led a high-level review of India's TB elimination programme, reaffirming the country's commitment to defeating the disease. But the official statement notably skipped mention of the 2025 deadline. Instead, it highlighted community-driven strategies - better sanitation, nutrition and social support for TB-affected families - as key to the fight. The government has also prioritised better diagnosis, treatment and prevention at the core of its elimination strategy. This approach mirrors the WHO's view of TB as a "disease of poverty". In its 2024 report, WHO chief Tedros Adhanom Ghebreyesus called it "the definitive disease of deprivation", noting how poverty, malnutrition and treatment costs trap patients in a vicious cycle. As India pushes toward its goal of eliminating the disease, deep health and social inequalities remain hurdles. With just six months left until India's self-imposed deadline, new complications have emerged. The fallout from US President Donald Trump's withdrawal from the WHO and suspension of USAID operations has raised concerns about future funding for global TB efforts. Since 1998, USAID has invested more than $140m to help diagnose and treat TB patients in India. However, India's federal health secretary insists there is "no budgetary problem" anticipated. Meanwhile, hope lies on the horizon. Sixteen TB vaccine candidates are currently in development across the world, with the WHO projecting potential availability within five years, pending successful trials.